mProX™ Human FCGR2A Stable Cell Line

Product Information

Target Family

Fc Receptor

Target Protein Species

Human

Host Cell Type

HEK293;CHO-K1;Primary human aortic smooth muscle cells (HAoSMCs)

Target Classification

Fc Receptor Cell Lines

Target Research Area

Metabolic Research

Related Diseases

Cystic Fibrosis; Systemic Lupus Erythematosus

Gene ID

Human:2212

UniProt ID

Human:P12318

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

FCGR2A, also known as Fc gamma receptor 2A, has been implicated in various diseases and conditions. In Parkinson's disease, FCGR2A is associated with the risk for PD based on a single pQTL after multiple corrections. In pemphigus vulgaris and pemphigus foliaceus, FCGR2A alleles/genotypes are differentially expressed. In diabetic retinopathy, FCGR2A is identified as one of the hub genes associated with the disease. In ABO-incompatible adult living donor liver transplantation, FCGR2A single-nucleotide polymorphisms (SNPs) are evaluated for their effect on rituximab therapy. In head and neck squamous cell carcinoma, FCGR2A is identified as a prognostic biomarker. These findings suggest that FCGR2A plays a role in the pathogenesis and prognosis of these diseases and conditions.

Protocols

Please visit our protocols page.

Customer Reviews

There are currently no Customer reviews or questions for mProX™ Human FCGR2A Stable Cell Line (S01YF-1023-PY157). Click the button above to contact us or submit your feedback about this product.

FAQ

chat Casey Brown (Verified Customer)

How does FCGR2A influence cardiovascular events after acute coronary syndrome? Apr 10 2021

chat Patrick Liam (Creative Biolabs Scientific Support)

FCGR2A gene variants can affect monocyte CD32 receptor expression, potentially impacting the risk of recurrent cardiovascular events following acute coronary syndrome. Apr 10 2021

chat Peyton Brown (Verified Customer)

Can FCGR2A polymorphism be a genetic marker for neonatal sepsis? Aug 17 2020

chat Patrick Liam (Creative Biolabs Scientific Support)

Yes, FcγRIIA genotyping, associated with FCGR2A, can serve as a marker of genetic susceptibility to sepsis in neonates. Aug 17 2020

Published Data

Fig.1 Blocking FCGR2A expression effectively hampers the activation of osteogenic pathways induced by CRP, leading to a significant reduction in the calcification process of human aortic smooth muscle cells (HAoSMCs).

Scatter dot plots and the corresponding means ± SEM (n=6; µg/mg protein) illustrating calcium levels in HAoSMCs following the knockdown of negative control siRNA (Neg.si) or FCGR2A siRNA (FR2Asi) and subsequent exposure to either control or calcification medium, along with 10 µg/ml recombinant human CRP (Calc.+CRP). Statistical significance is denoted as *(p<0.05), **(p<0.01), ***(p<0.001) when compared to Neg.si silenced HAoSMCs, and ††(p<0.01), †††(p<0.001) when compared to Neg.si silenced HAoSMCs subjected to CRP/Calc.+CRP treatment.

Ref: Henze, Laura A., et al. "Impact of C-reactive protein on osteo-/chondrogenic transdifferentiation and calcification of vascular smooth muscle cells." Aging (Albany NY) 11.15 (2019): 5445.

Pubmed: 31377747

DOI: 10.18632/aging.102130

Research Highlights

Gu, Xiao-Jing. et al. "Expanding causal genes for Parkinson's disease via multi-omics analysis." NPJ Parkinson's disease, 2023.
The results of the study showed that GPNMB played a significant causal role in PD at the protein level in blood, cerebrospinal fluid (CSF), and brain tissues. It also showed a potential protective role of CD38, identified through analysis of brain pQTL and eQTL data. Additionally, inconsistency between protein and mRNA levels was observed for the role of DGKQ in PD. The study also identified nine other proteins (CTSB, ARSA, SEC23IP, CD84, ENTPD1, FCGR2B, BAG3, SNCA, FCGR2A) that were associated with PD risk based on only a single pQTL after multiple corrections were applied. The researchers also identified interactions between some of these proteins and known PD causative genes and therapeutic targets. In conclusion, this study provides evidence that GPNMB, CD38, and DGKQ may play a role in the pathogenesis of PD, but further research is needed to confirm the involvement of other proteins in the disease. These findings contribute to a better understanding of the genes underlying PD and highlight potential targets for future therapeutic interventions.
Gu, Xiao-Jing. et al. "Expanding causal genes for Parkinson's disease via multi-omics analysis." NPJ Parkinson's disease, 2023.
Pubmed: 37865667 DOI: 10.1038/s41531-023-00591-0

Dai, Yongmei et al. "FCGR2A Could Function as a Prognostic Marker and Correlate with Immune Infiltration in Head and Neck Squamous Cell Carcinoma." BioMed research international vol. 2021 8874578. 5 Jul. 2021.
The study's objective was to explore the association between FCGR2A mRNA levels and the prognosis of head and neck squamous cancer (HNSC) using publicly available databases. Additionally, it investigated the connection between FCGR2A expression, clinicopathological characteristics, and the presence of tumor-infiltrating immune cells in HNSC patients. Their approach involved analyzing FCGR2A mRNA expression across multiple cancer types, constructing a protein-protein interaction network, and identifying the ten proteins most closely linked to FCGR2A. The study observed significantly elevated FCGR2A expression in various carcinoma tissues compared to adjacent tissues, with notable distinctions in HNSC samples across different grades. The FCGR2A gene exhibited correlations with distal HNSC metastasis and survival outcomes, as validated by the GSE65858 dataset. These findings underscore the relevance of FCGR2A in HNSC and its potential involvement in tumor-immune interactions.
Dai, Yongmei et al. "FCGR2A Could Function as a Prognostic Marker and Correlate with Immune Infiltration in Head and Neck Squamous Cell Carcinoma." BioMed research international vol. 2021 8874578. 5 Jul. 2021.
Pubmed: 34285919 DOI: 10.1155/2021/8874578